ClinicalTrials.gg
RecruitingNCT06676137CCMDUpdated Aug 20, 2025

An Observational Study of Coronary Microvascular Disease of China

An observational study in Coronary Microvascular Disease, sponsored by Henan Institute of Cardiovascular Epidemiology. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Henan Institute of Cardiovascular Epidemiology · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Microvascular Angina with a site in China — 9 open to participants now, 9 under way, none of them phase 3. Microvascular Angina · China.

Started
2024
with 1 other
Observational
5 of 15
3 open now
Registered
10th of 15
by date
Lead sponsor
1 of 15
Henan Institute of Cardiovascular Epidemiology

Among the 15 studies in Microvascular Angina with a site in China, this one is one of 2 that started in 2024, is one of 5 observational ones, and was the 10th registered.

Microvascular Angina

111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.

Browse Microvascular Angina studies →

Open to participants now

9 of the 15 studies in Microvascular Angina with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Microvascular Angina studies recruiting now, 17 (63%) set no upper age limit and 3 (11%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Microvascular Angina with a site in China, or all of them as a file.
02

Study summary

Non-obstructive coronary heart disease refers to patients with angina pectoris without significant narrowing of the epicardial vessels. Coronary microvascular disease(CMD) is a kind of non-obstructive coronary heart disease, and its clinical detection rate is increasing, seriously affecting the quality of life of patients, and increasing the risk of cardiovascular adverse events, but its mechanism has not been fully understood. This study will prospectively collect patients who meet the diagnosis of CMD, observe the development and outcome of the disease, and explore its occurrence and development mechanism.

03

Conditions studied

  • Coronary Microvascular Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patient had obvious symptoms of angina pectoris, but coronary angiography showed no obvious epicardial stenosis, and auxiliary examinations such as ultrasound, CTP,CMR, PET, SPECT, and coronary function examination indicate the presence of microcirculation dysfunction

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Angina symptoms
  2. Objective evidence of myocardial ischemia
  3. Coronary angiography was normal,irregular tube wall, or stenosis \<50%

Exclusion criteria

Exclusion Criteria:

  1. People under the age of 18
  2. Non-cardiogenic chest pain and other heart conditions such as variant angina, cardiomyopathy, myocarditis or valvular heart disease
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Establish a Registry of CMD patients in China

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Fuwai central China cardiovascular hospotial
    Zhengzhou, 450003, China
    Recruiting
    • Quan Guo · Contactxinyiguoquan@163.com · +8615670510031
    • Yang Gao · Principal investigator
    • Qingbo Shi · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Oct 2028, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 6, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Oct 10, 2028
CompletionEst.
Oct 10, 2029
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06676137
Lead sponsor
Henan Institute of Cardiovascular Epidemiology
Responsible party
Sponsor
First posted
Nov 6, 2024
Start date
Nov 11, 2024
Primary completion
Oct 10, 2028 (estimated)
Completion
Oct 10, 2029 (estimated)
Last update
Aug 20, 2025

Study contacts

Quan Guo
Contact
xinyiguoquan@163.com
+8615670510031
muwei li, Ph.D
study chair · Fuwai central China cardiovascular hospotial

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion